PracticeUpdate: Conference Series | ADC 2018

1 0 Y E A R S SUPPORTING T2DM PATIENTS I N A U S T R A L I A 1

3 reasons to choose JANUVIA as your DPP4i of choice in T2DM

with JANUVIA added to patients uncontrolled onmetformin 2 -1.1% HbA1c reductions with JANUVIA (n=82) from a baseline HbA1c of ≥8-<9% at week 52 vs -1.1% for glipizide (n=82) when added to metformin (subgroup of primary endpoint) 2

Strong HbA1c reductions 2

Any stage of renal impairment 1 Demonstrated CV safety profile 5

with dose adjustment where eGFR <50ml/min/1.73m 2 3,4

in patients with established CVD when added to usual care 5 *

* Usual care consisted of open label antihyperglycaemic agents as required during the study, with the aim of achieving individually appropriate HbA1c targets in all patients. Study designs provided in primary advertisement in this publication. CV=cardiovascular, CVD=cardiovascular disease, DPP4i=dipeptidyl peptidase-4 inhibitor, eGFR=estimated glomerular filtration

Before prescribing please review the PBS and Product Information in the primary advertisement in this publication. References: 1. JANUVIA Approved Product Information, April 2017. 2. Nauck MA et al. Diabetes Obes Metab 2007;9(2):194–205. 3. Arjona Ferreira JC et al. Am J Kidney Dis

2013;61(4): 579-587. 4. Arjona Ferreira JC et al. Diabetes Care 2013;36(5): 1067-1073. 5. Green JB et al. N Engl J Med 2015; 373(3): 232–242. Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. DIAB-1268045-0000. First Issued August 2018. Bloe Agency MSD13139.